Related Experiment Video
Updated: Mar 1, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine
Jung Wook Yang1, Yoon-La Choi2
1Department of Pathology, Gyeongsang National University School of Medicine, Jinju, South Korea.
Purpose:
Preparing for precision medicine, we surveyed genomic alterations in esophageal squamous cell carcinoma (ESCC) and identified candidate therapeutic targets by genomic profiling using next-generation sequencing (NGS).
Materials And Methods:
Single-nucleotide variations, indels, and copy number variations in 80 genes were evaluated by targeted deep sequencing in 24 surgically resected ESCC specimens. Immunohistochemistry analyses and silver in situ hybridization for ERBB2 (HER2) were conducted to verify the NGS results. Associations between clinicopathological factors and detected genomic alterations were estimated.
Results:
The mean coverage of sequencing of the tumor tissues from 24 patients was 464.8X with 85.1% over 100X. We detected a total of 115 genetic alterations and more than one genetic alteration was detected in most patients (23/24, 95.8%). Genes with genetic alterations detected in more than 20% of cases included TP53 (20/24, 83%), NOTCH1 (7/24, 29%), and MTOR (6/24, 25%). Amplification of 7 genes was detected in 8 cases. Genes showing amplification included AKT2 (1/24, 4.2%), EGFR (2/24, 8.3%), ERBB2 (HER2; 1/24, 4.2%), FGFR1 (1/24, 4.2%), KRAS (1/24, 4.2%), MDM2 (1/24, 4.2%), and PIK3CA (1/24, 4.2%). The ERBB2 alteration was confirmed by immunohistochemistry and silver in situ hybridization. Patients with NF1 and ARID1A mutations were younger than the patients without the mutations. (p=0.024 and 0.014, respectively). NOTCH1 mutation and EGFR genetic alteration were associated with a larger tumor size (p=0.019) and lesser invasion depth (p=0.005), respectively.
Conclusion:
This study revealed the genetic profiles of ESCC, which may provide a foundation for the development of novel targeted therapy and precision medicine.
Insights
Genomic profiling of esophageal squamous cell carcinoma (ESCC) revealed frequent alterations in TP53, NOTCH1, and MTOR. These findings support the development of targeted therapies for precision medicine in ESCC treatment.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Esophageal squamous cell carcinoma (ESCC) is a significant global health concern.
- Understanding the genomic landscape of ESCC is crucial for developing effective precision medicine strategies.
Purpose of the Study:
- To survey genomic alterations in ESCC using next-generation sequencing (NGS).
- To identify potential therapeutic targets for ESCC through comprehensive genomic profiling.
Main Methods:
- Targeted deep sequencing of 80 genes in 24 ESCC specimens.
- Analysis of single-nucleotide variations, indels, and copy number variations.
- Validation of ERBB2 (HER2) alterations using immunohistochemistry and silver in situ hybridization.
Main Results:
- Most patients (95.8%) exhibited multiple genetic alterations.
- Frequent alterations were observed in TP53 (83%), NOTCH1 (29%), and MTOR (25%).
- Amplifications were detected in genes including EGFR and ERBB2; NF1 and ARID1A mutations correlated with younger patient age.
Conclusions:
- This study elucidates the genetic profiles of ESCC.
- The identified genomic alterations provide a foundation for novel targeted therapies.
- Findings pave the way for advancing precision medicine approaches in ESCC.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Pharmacogenomics: Identification of New Drug Targets